Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

H. Mukai · SciRah

Researcher profile · Semantic Scholar

H. Mukai

Share profile

H. Mukai — researcher profile on SciRah

h-index: 39
Works: 297
Citations: 7,191

Most-cited papers

Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
S. Adams, S. Loi, D. Toppmeyer, D. Cescon +16 more
2019Annals of Oncology584 citations Open access
Semantic Scholar
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials
R. Gray, Rosie Bradley, J. Braybrooke, Zu-Lian Liu +162 more
2019The Lancet328 citations Open access
Semantic Scholar
Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials
Rosie Bradley, J. Braybrooke, R. Gray, R. Hills +96 more
2021The Lancet Oncology259 citations Open access
Semantic Scholar
Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials
Rosie Bradley, J. Braybrooke, R. Gray, R. Hills +86 more
2022The Lancet Oncology210 citations Open access
Semantic Scholar
Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site.
H. Hayashi, T. Kurata, Y. Takiguchi, M. Arai +17 more
2019Journal of Clinical Oncology133 citations
Semantic Scholar
A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients
Y. Fujiwara, H. Mukai, T. Saeki, J. Ro +13 more
2019British Journal of Cancer119 citations Open access
Semantic Scholar
Efficacy and safety of nivolumab in Japanese patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma: Multicenter, open‐label phase 2 trial
K. Tamura, K. Hasegawa, N. Katsumata, Koji Matsumoto +4 more
2019Cancer Science91 citations Open access
Semantic Scholar
Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study
S. Im, H. Mukai, I. Park, N. Masuda +12 more
2019Journal of Global Oncology89 citations Open access
Semantic Scholar
Randomized Controlled Trial of Trastuzumab With or Without Chemotherapy for HER2-Positive Early Breast Cancer in Older Patients.
M. Sawaki, N. Taira, Y. Uemura, Tsuyoshi Saito +17 more
2020Journal of Clinical Oncology71 citations Open access
Semantic Scholar
Venous thromboembolism in cancer patients: report of baseline data from the multicentre, prospective Cancer-VTE Registry
Y. Ohashi, M. Ikeda, H. Kunitoh, M. Sasako +8 more
2020Japanese Journal of Clinical Oncology65 citations Open access
Semantic Scholar
Pembrolizumab Plus Chemotherapy Followed by Pembrolizumab in Patients With Early Triple-Negative Breast Cancer
Masato Takahashi, J. Cortés, R. Dent, L. Pusztai +16 more
2023JAMA Network Open49 citations Open access
Semantic Scholar
Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial.
M. Toi, S. Imoto, T. Ishida, Y. Ito +21 more
2021The Lancet Oncology45 citations
Semantic Scholar
Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2.
H. Rugo, R. Finn, K. Gelmon, A. Joy +10 more
2019Clinical Breast Cancer32 citations Open access
Semantic Scholar
One-year incidence of venous thromboembolism, bleeding, and death in patients with solid tumors newly initiating cancer treatment: Results from the Cancer-VTE Registry.
Y. Ohashi, M. Ikeda, H. Kunitoh, M. Sasako +9 more
2021Thrombosis Research31 citations Open access
Semantic Scholar
Oral Care Evaluation to Prevent Oral Mucositis in Estrogen Receptor‐Positive Metastatic Breast Cancer Patients Treated with Everolimus (Oral Care‐BC): A Randomized Controlled Phase III Trial
N. Niikura, K. Nakatukasa, T. Amemiya, Ken-ichi Watanabe +16 more
2019The Oncologist27 citations Open access
Semantic Scholar
Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy
K. Inoue, N. Masuda, H. Iwata, Masato Takahashi +12 more
2021Breast Cancer24 citations Open access
Semantic Scholar
Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer: results of a randomised Phase 2 study
H. Mukai, Takeshi Yamaguchi, Masato Takahashi, Y. Hozumi +13 more
2020British Journal of Cancer21 citations Open access
Semantic Scholar
Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor–Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial
T. Iwase, S. Saji, K. Iijima, K. Higaki +14 more
2023Journal of Clinical Oncology18 citations
Semantic Scholar
Effectiveness and safety of eribulin in Japanese patients with HER2-negative, advanced breast cancer: a 2-year post-marketing observational study in a real-world setting
K. Inoue, Masato Takahashi, H. Mukai, T. Yamanaka +5 more
2020Investigational new drugs18 citations Open access
Semantic Scholar
Minimal important differences of EORTC QLQ-C30 for metastatic breast cancer patients: Results from a randomized clinical trial
Takuya Kawahara, N. Taira, T. Shiroiwa, Y. Hagiwara +3 more
2022Quality of Life Research17 citations Open access
Semantic Scholar
Multi-omics analyses identify HSD17B4 methylation-silencing as a predictive and response marker of HER2-positive breast cancer to HER2-directed therapy
S. Yamashita, Naoko Hattori, S. Fujii, Takeshi Yamaguchi +10 more
2020Scientific Reports17 citations Open access
Semantic Scholar
Anthracycline-containing regimens or taxane versus S-1 as first-line chemotherapy for metastatic breast cancer
H. Mukai, Y. Uemura, H. Akabane, Takanori Watanabe +8 more
2021British Journal of Cancer16 citations Open access
Semantic Scholar
Neutropenia management with palbociclib in Japanese patients with advanced breast cancer
N. Masuda, H. Mukai, K. Inoue, Y. Rai +7 more
2019Breast Cancer16 citations Open access
Semantic Scholar
Abstract GS3-04: A prospective randomized multi-center open-label phase III trial of extending aromatase-inhibitor adjuvant therapy to 10 years - Results from 1697 postmenopausal women in the N-SAS BC 05 trial: Arimidex extended adjuvant randomized study (AERAS)
S. Ohtani, K. Iijima, K. Higaki, Yasuyuki Sato +15 more
2019General Session Abstracts14 citations
Semantic Scholar
Efficacy of Telemedicine Using Videoconferencing Systems in Outpatient Care for Patients With Cancer: A Systematic Review and Meta-Analysis.
Yasuaki Uemoto, Taro Yamanaka, Y. Kataoka, Y. Wada +6 more
2022JCO Clinical Cancer Informatics13 citations
Semantic Scholar
Prospective cohort study of febrile neutropenia in breast cancer patients administered with neoadjuvant and adjuvant chemotherapies: CSPOR-BC FN study
T. Ishikawa, K. Sakamaki, K. Narui, H. Nishimura +12 more
2021Breast13 citations Open access
Semantic Scholar
Health-Related Quality of Life With Trastuzumab Monotherapy Versus Trastuzumab Plus Standard Chemotherapy as Adjuvant Therapy in Older Patients With HER2-Positive Breast Cancer
N. Taira, M. Sawaki, Y. Uemura, Tsuyoshi Saito +17 more
2021Journal of Clinical Oncology13 citations
Semantic Scholar
Randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer
J. Tsurutani, F. Hara, M. Kitada, Masato Takahashi +12 more
2020Breast13 citations Open access
Semantic Scholar
Association of change in health-related quality of life and treatment discontinuation in metastatic breast cancer: a post hoc, exploratory analysis of two randomized clinical trials
Takuya Kawahara, T. Iwamoto, Ikumi Takashima, R. Hanazawa +5 more
2022Supportive Care in Cancer12 citations Open access
Semantic Scholar
Indices of peripheral leukocytes predict longer overall survival in breast cancer patients on eribulin in Japan
Masato Takahashi, K. Inoue, H. Mukai, T. Yamanaka +7 more
2021Breast Cancer12 citations Open access
Semantic Scholar
Association of D-dimer level with thrombotic events, bleeding, and mortality in Japanese patients with solid tumors: a Cancer-VTE Registry subanalysis
Mashio Nakamura, Masato Sakon, M. Sasako, T. Okusaka +8 more
2024International Journal of Clinical Oncology11 citations Open access
Semantic Scholar
Oral care and oral assessment guide in breast cancer patients receiving everolimus and exemestane: subanalysis of a randomized controlled trial (Oral Care-BC)
M. Umeda, Y. Ota, K. Kashiwabara, N. Hayashi +16 more
2020Annals of Translational Medicine11 citations Open access
Semantic Scholar
A deep learning-based automated diagnostic system for classifying mammographic lesions
Takeshi Yamaguchi, K. Inoue, H. Tsunoda, T. Uematsu +2 more
2020Medicine11 citations Open access
Semantic Scholar
NSAS-BC02 substudy of chemotherapy-induced amenorrhea (CIA) in premenopausal patients who received either taxane alone or doxorubicin(A) cyclophosphamide(C) followed by taxane as postoperative chemotherapy
T. Iwamoto, F. Hara, Y. Uemura, H. Mukai +2 more
2020Breast Cancer Research and Treatment10 citations
Semantic Scholar
Adjuvant trastuzumab without chemotherapy for treating early HER2-positive breast cancer in older patients: A propensity score-adjusted analysis of a prospective cohort study
M. Sawaki, N. Taira, Y. Uemura, Tsuyoshi Saito +18 more
2022Breast9 citations Open access
Semantic Scholar
The impact of neoadjuvant systemic therapy on breast conservation rates in patients with HER2-positive breast cancer: Surgical results from a phase II randomized controlled trial.
Takeshi Yamaguchi, Y. Hozumi, Yasuaki Sagara, Masato Takahashi +7 more
2020Surgical oncology9 citations Open access
Semantic Scholar
Analysis of subsequent therapy in Japanese patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer who received palbociclib plus endocrine therapy in PALOMA-2 and -3
N. Masuda, H. Mukai, K. Inoue, Y. Rai +8 more
2020Breast Cancer8 citations Open access
Semantic Scholar
DNA methylation marker to estimate the breast cancer cell fraction in DNA samples
Hiroki Ishihara, S. Yamashita, S. Fujii, K. Tanabe +2 more
2018Medical Oncology8 citations Open access
Semantic Scholar
Venous thromboembolism in Japanese patients with breast cancer: subgroup analysis of the Cancer-VTE Registry
S. Ohsumi, Kenichi Watanabe, Naoto Kondo, Y. Kosaka +7 more
2023Breast Cancer7 citations Open access
Semantic Scholar
Participants in a randomized controlled trial had longer overall survival than non-participants: a prospective cohort study
S. Ohno, H. Mukai, K. Narui, Y. Hozumi +12 more
2019Breast Cancer Research and Treatment7 citations
Semantic Scholar
A randomized study comparing electronic patient-reported outcome (ePRO) monitoring with routine follow-up during trastuzumab deruxtecan treatment in patients with metastatic breast cancer (PRO-DUCE study).
Y. Kikawa, Yukari Uemura, T. Taira, C. Kitagawa +16 more
2024Journal of Clinical Oncology6 citations
Semantic Scholar
The efficacy of sequential second-line endocrine therapies (ETs) in postmenopausal estrogen receptor-positive and HER2-negative metastatic breast cancer patients with lower sensitivity to initial ETs
T. Iwamoto, T. Fujisawa, T. Shien, K. Araki +9 more
2020Breast Cancer6 citations Open access
Semantic Scholar
Impact of chemotherapy on cognitive functioning in older patients with HER2-positive breast cancer: a sub-study in the RESPECT trial
Y. Hagiwara, M. Sawaki, Y. Uemura, Takuya Kawahara +8 more
2021Breast Cancer Research and Treatment5 citations
Semantic Scholar
Use of eribulin as an earlier-line chemotherapy for patients with HER2-negative metastatic breast cancer
S. Shingaki, T. Kogawa, M. Shimokawa, K. Harano +9 more
2020Journal of Cancer5 citations Open access
Semantic Scholar
HSD17B4 methylation enhances glucose dependence of BT-474 breast cancer cells and increases lapatinib sensitivity
Nobuaki Arai, Naoko Hattori, S. Yamashita, Yu-Yu Liu +7 more
2023Breast Cancer Research and Treatment4 citations
Semantic Scholar
Prospective Cohort Study of Combination Therapy With Abemaciclib and Hormonal Therapy for Chemotherapy-Treated Patients With Hormone Receptor-Positive Metastatic Breast Cancer
Kana Miyahara, K. Narui, Y. Uemura, A. Yamada +8 more
2022World Journal of Oncology4 citations Open access
Semantic Scholar
Secondary endpoints analysis in patients with estrogen receptor-positive metastatic breast cancer treated with everolimus and exemestane enrolled in Oral Care-BC
K. Nakatsukasa, N. Niikura, K. Kashiwabara, T. Amemiya +16 more
2021BMC Cancer4 citations Open access
Semantic Scholar
Abstract GS1-09: Addition of S-1 to endocrine therapy in the post-operative adjuvant treatment of hormone receptor-positive and human epidermal growth factor receptor 2-negative primary breast cancer: A multicenter, open-label, phase 3 randomized trial (POTENT trial)
M. Toi, S. Imoto, T. Ishida, Y. Ito +21 more
2020General Session Abstracts4 citations
Semantic Scholar
Sensitivity analysis for subsequent treatments in confirmatory oncology clinical trials: A two‐stage stochastic dynamic treatment regime approach
Y. Hagiwara, T. Shinozaki, H. Mukai, Y. Matsuyama
2020Biometrics4 citations
Semantic Scholar
Randomized, optimal dose-finding, phase II study of tri-weekly nab-paclitaxel in patients with metastatic breast cancer (ABROAD).
F. Hara, M. Kitada, Masato Takahashi, Y. Kikawa +12 more
2019Journal of Clinical Oncology4 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

Masato Takahashi×14
Invite
Masato Takahashi — researcher profile on SciRah
Y. Ohashi×13
Invite
Y. Ohashi — researcher profile on SciRah
N. Taira×12
Invite
N. Taira — researcher profile on SciRah
H. Iwata×11
Invite
H. Iwata — researcher profile on SciRah

×11

Invite

Y. Uemura — researcher profile on SciRah

Invite

Y. Kikawa — researcher profile on SciRah

Invite

M. Toi — researcher profile on SciRah

T. Takashima×7

Invite

T. Takashima — researcher profile on SciRah

Takuya Kawahara×7

Invite

Takuya Kawahara — researcher profile on SciRah

Invite

Y. Hozumi — researcher profile on SciRah

Invite

N. Masuda — researcher profile on SciRah

Invite

K. Inoue — researcher profile on SciRah